Infliximab (Remicade)

Browse eMedTV's wide range of articles related to infliximab (remicade) including topics such as generic infliximab, infliximab dosing, and infliximab side effects. Use the search box at the top-right corner of the page to find information about other health topics.

 Read About 
 
Description of Articles in Infliximab (Remicade)

Infliximab is a prescribed drug for inflammatory conditions affecting the joints, skin, and digestive tract. This eMedTV resource explains how infliximab works, lists side effects, and covers what to tell your physician prior to taking the drug.

Some common side effects of infliximab can include headaches, infections, and anemia. This eMedTV segment also outlines some of the more serious infliximab side effects that may need medial attention, such as unusual bleeding or difficulty breathing.

What is infliximab used for? This eMedTV page discusses how the drug helps relieve inflammatory conditions of the joints, skin, and digestive system. This page also highlights some off-label uses of the drug and describes who can use the medication.

Your infliximab dose will vary based on several factors, such as your weight and what condition you have. This eMedTV page highlights infliximab dosing recommendations on when and how to take the infusions, and explains how the dosage is determined.

This portion of the eMedTV Web site explores potential drug interactions with infliximab and other medications, such as live vaccines, anakinra, and etanercept. This article also describes the problems that can occur with these drug interactions.

This eMedTV Web page examines several precautions and warnings with infliximab, such as an increased risk of lymphoma and the danger of taking the medication if you have an infection. This page also lists those who should not take the drug.

There may never be a generic infliximab available because the medication is considered a "biologic." This eMedTV segment explains why generic biologics are not manufactured and also warns people about companies claiming to sell a generic infliximab.